Impact of fecal sludge and municipal solid waste co-compost on crop growth of Raphanus Sativus\textit {Raphanus Sativus} L. and Capsicum Anuum\textit {Capsicum Anuum} L. under stress conditions

Co-composted dewatered faecal sludge (FS) with organic fractions of municipal solid waste (MSW) has a high potential to be used as an agricultural resource in Sri Lanka. In addition to options for cost recovery in waste management, closing the nutrient and carbon cycles between urban and rural areas, substitution of mineral fertilizers, reduced pollution. and the restoration of degraded arable land are possible with important benefits. Up to now little is known about the usage of FS-MSW as fertilizer and it needs to be studied in order to achieve a better understanding and generate application recommendations. The aim of these experiments has been to evaluate the possibility of substituting mineral fertilization. Two field experiments were conducted on sandy loam to assess the effects of MSW compost and FS-MSW co-compost, its pelletized forms, and mineral-enriched FS-MSW on crop growth. As a short-term crop $\textit {Raphanus sativus}$ "Beeralu rabu" (radish) was studied for 50 days in a randomized complete block design (RCDB). Results show that, under drought conditions, FS-MSW co-compost increased the yield significantly, while MSW and FS-MSW compost enabled the highest survival rate of the plants. Similarly, the second field trial with a long-term crop, $\textit {Capsicum anuum}$ "CA-8" (capsicum), was planted as RCBD, using the same treatments, for a cultivation period of 120 days. Results display that during a drought followed by water saturated soil conditions co-compost treatments achieved comparable yields and increased the survival rate significantly compared to the control, fertilized with urea, triple super phosphate, and muriate of potash. Cost-benefit analysis (CBA) revealed that pelletizing decreased the monetary benefits if only fertilizer value is considered. It can be concluded that, under drought and water stress, co-compost ensures comparable yields and enables more resistance, but might not be economical viable as a one-crop fertilizer. These findings need to be validated with further trials under different climate regimes and soil

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit